Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1/PD-L1 Inhibitor and Lenvatinib in Pediatric Liver Tumors
NCT05322187Phase 3Unknown
- Sponsor
- Renji Hospital
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenvatinib in Combined hepatocellular-cholangiocarcinoma (cHCC-CC) and hepatoblastoma, sponsored by Renji Hospital. Primary endpoints: Objective Response Rate at 1 year and Dynamic alpha-fetoprotein response at 6 months. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)hepatoblastoma
Beyond the preview
Go deeper on NCT05322187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322187.